**Table 1: 2023 ICD-O-3.2 Update (Numerical)**

* Codes/terms listed numerically
* Only new terminology to existing ICD-O-3.2 codes are included in the 2023 ICD-O Implementation guidelines and documentation. Terms are those listed in WHO Blue Books
* Update based on the following 5th Ed Classification of Tumors books: Thoracic and CNS

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **ICD-O****Code** | **Term** | **Required****SEER** | **Required****NPCR** | **Required** **CoC** | **Required****CCCR** | **Remarks** |
| 8044/3 | Thoracic SMARCA4-deficient undifferentiated tumor (C34.\_) | Y | Y | Y | Y | New term |
| 8077/2 | Moderate squamous dysplasiaSevere squamous dysplasia | NSee remarks\* | NSee remarks\* | NSee remarks\* | NSee remarks\* | New term. \*Note: moderate and severe squamous dysplasia are incidental findings on bronchoscopy. Considered precursor to squamous carcinoma in situ (SCIS).**Reportability has not yet been determined.** |
| 8140/0 | Bronchiolar adenoma/ciliated muconodular papillary tumor | N | N | N | N | New terms/Not reportable |
| 8260/3 | Low-grade papillary adenocarcinoma  | Y | Y | Y | Y | New term |
| 8272/3 | Pituitary adenoma/pituitary neuroendocrine tumor (PitNET) **(C75.1)** | Y | Y | Y | Y | New term. Per WHO, both terms may be used in the diagnosis or pituitary neuroendocrine tumor, or PitNET. All are coded 8272/3. Pituitary adenoma, NOS is coded 8272/0 |
| 8310/3  | Hyalinizing clear cell carcinoma | Y | Y | Y | Y | New term |
| 8693/3 | Cauda equina neuroendocrine tumor (cranial and paraspinal nerves) | Y | Y | Y | Y | New related term |
| 8820/0 | Papillary fibroelastoma | N | N | N | N | New term/not reportable |
| 8821/1 | Desmoid fibromatosis | N | N | N | N | New term/not reportable |
| 9050/2 | Mesothelioma in situ  | Y | Y | Y | Y | New code/behavior. Reportable 1/1/2023 |
| 9050/3 | Localized pleural mesothelioma **(C38.4)**Diffuse pleural mesothelioma **(C38.4)** | YY | YY | YY | YY | New termNew term |
| 9170/3 | Diffuse pulmonary lymphangiomatosis **(C34.\_)** | Y | Y | Y | Y | New term |
| 9174/3 | Lymphangioleiomyomatosis | Y | Y | Y | Y | Behavior code change from /1 to /3. Reportable for cases diagnosed 1/1/2023 forward. |
| 9385/3 | Diffuse midline glioma, H3 K27-altered Diffuse hemispheric glioma, H3 G34-mutant Diffuse pediatric-type glioma, H3-wildtype and IDH-wildtype Infant-type hemispheric glioma  | YYYY | YYYY | YYYY | YYYY | New termNew termNew termNew term |
| 9391/3 | Supratentorial ependymoma, NOS **(C71.\_)**Posterior fossa ependymoma, NOS **(C71.\_)**Spinal ependymoma, NOS **(C72.0)** | YYY | YYY | YYY | YYY | New termNew termNew term |
| 9396/3 | Supratentorial ependymoma, ZFTA fusion-positive Supratentorial ependymoma, YAP1 fusion-positive Posterior fossa group A (PFA) ependymomaPosterior fossa group B (PFB) ependymomaSpinal ependymoma, MYCN-amplified **(C72.0)** | YYYYY | YYYYY | YYYYY | YYYYY | New termNew termNew termNew termNew term |
| 9400/3 | Astrocytoma, IDH-mutant, grade 2 | Y | Y | Y | Y | New term |
| 9401/3 | Astrocytoma, IDH-mutant, grade 3 | Y | Y | Y | Y | New term |
| 9413/0 | Polymorphous low-grade neuroepithelial tumor of the young | Y | Y | Y | Y | New term |
| 9421/1 | **Diffuse astrocytoma, *MYB*- or *MYBL1*-altered**Diffuse low-grade glioma, MAPK pathway–altered† | YY | YY | YY |  | Replaces the term “pilocytic astrocytoma”**Beginning with cases diagnosed 1/1/2023, pilocytic astrocytoma are coded 9421/1**. **Cases diagnosed prior to 1/1/2023 are coded 9421/3.**  |
| 9421/3 | **High-grade astrocytoma with piloid features (HGAP)** | Y | Y | Y |  | New code/new term. **Beginning 1/1/2023, cases diagnosed as *high-grade astrocytoma with piloid features (HGAP)* are coded 9421/3.** Beginning 1/1/2023, cases diagnosed as Pilocytic astrocytoma in the C71.\_ are to be coded 9421/1 |
| 9430/3 | Astroblastoma, MN1-altered | Y | Y | Y | Y | New term |
| 9445/3 | Astrocytoma, IDH-mutant, grade 4 | Y | Y | Y | Y | New term |
| 9450/3 | Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, grade 2 | Y | Y | Y | Y | New term |
| 9451/3 | Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, grade 3 | Y | Y | Y | Y | New term |
| 9470/3 | Medulloblastoma, histologically defined **(C71.6)** | Y | Y | Y | Y | New term |
| 9473/3 | CNS embryonal tumor, NEC/NOS | Y | Y | Y | Y | New term |
| 9480/3 | Primary intracranial sarcoma, DICER1-mutant **(C71.6)** | Y | Y | Y | Y | New term |
| 9500/3 | CNS neuroblastoma, FOXR2-activatedCNS tumor with BCCR internal tandem duplication | YY | YY | YY | YY | New termNew term |
| 9509/0 | Multinodular and vacuolating neuronal tumor | Y | Y | Y | Y | New code/new term/new behaviorCases diagnoses prior to 1/1/2023 use code 9505/0. Cases diagnosed 1/1/2023 forward use code 9509/0. |
| 9509/1 | Myxoid glioneuronal tumor | Y | Y | Y | Y | New term |
| 9509/3 | Diffuse leptomeningeal glioneuronal tumor | Y | Y | Y | Y | New code/new term/new behavior |
| 9540/3 | Malignant melanotic nerve sheath tumor | Y | Y | Y | Y | New term |
| 9680/3  | Diffuse large B-cell lymphoma associated with chronic inflammation of the pleura **(C38.4)**Fibrin-associated diffuse B-cell lymphoma **(C38.0)** | YY | YY | YY | YY | New termNew term |
| 9699/3 | MALT lymphoma of the dura | Y | Y | Y | Y | New term |
| 9749/1 | Juvenile xanthogranuloma **(C71.5)** | Y | Y | Y | Y | New code/new term/new behavior |
| 9749/3 | Rosai-Dorfman disease | Y | Y | Y | Y | New term |